Drug Trial Radar · NCT05741476
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Feb 21, 2023
Primary completion
Nov 6, 2025
Study completion Oct 2029
Sponsor
- Lead sponsor
- DBV TechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Conditions
- Allergy, Peanut
Interventions
DBV712Drug
DBV712 250 mcg epicutaneous system.
PlaceboOther
DBV712 matching placebo epicutaneous system.
DBV712Drug
DBV712 250 mcg epicutaneous system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DBPC Treatment Period: Percentage of Treatment Responders in the DBV712 250 mcg Group Compared to Placebo GroupTime frame: At Month 12
Locations
87 sites in 9 countries. Site status is shown where the registry gives one.
DBV Investigative Site
Birmingham, Alabama
DBV Investigative Site
Tucson, Arizona
DBV Investigative Site
Little Rock, Arkansas
DBV Investigative Site
Los Angeles, California
DBV Investigative Site
Los Angeles, California
DBV Investigative site
Mission Viejo, California
DBV Investigative Site
San Diego, California
DBV Investigative Site
San Francisco, California
DBV Investigative Site
San Jose, California
DBV Investigative Site
Aurora, Colorado
DBV Investigative Site
Colorado Springs, Colorado
DBV Investigative Site
Washington D.C., District of Columbia
DBV Investigative Site
Hollywood, Florida
DBV Investigative Site
Miami, Florida
DBV Investigative Site
St. Petersburg, Florida
DBV Investigative Site
Tampa, Florida
DBV Investigative site
Atlanta, Georgia
DBV Investigative Site
Marietta, Georgia
DBV Investigative Site
Chicago, Illinois
DBV Investigative Site
Normal, Illinois
DBV Investigative Site
Indianapolis, Indiana
DBV Investigative Site
Louisville, Kentucky
DBV Investigative Site
Baltimore, Maryland
DBV Investigative Site
Chevy Chase, Maryland
DBV Investigative Site
Boston, Massachusetts
DBV Investigative Site
Boston, Massachusetts
DBV Investigative Site
Taunton, Massachusetts
DBV Investigative Site
Ann Arbor, Michigan
DBV Investigative Site
Ypsilanti, Michigan
DBV Investigative Site
Maplewood, Minnesota
DBV Investigative Site
Kansas City, Missouri
DBV Investigative Site
Great Neck, New York
DBV Investigative Site
New York, New York
DBV Investigative Site
New York, New York
DBV Investigative Site
Rochester, New York
DBV Investigative Site
Chapel Hill, North Carolina
DBV Investigative Site
Cincinnati, Ohio
DBV Investigative Site
Cleveland, Ohio
DBV Investigative Site
Cleveland, Ohio
DBV Investigative Site
Columbus, Ohio
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.